URB597 - Moligand™, 10mM in DMSO , Inhibitor of Fatty acid amide hydrolase;Inhibitor of Fatty acid amide hydrolase-2;Activator of TRPA1, CAS No.546141-08-6, Inhibitor of Fatty acid amide hydrolase;Inhibitor of Fatty acid amide hydrolase-2;Activator of TRPA1

CAS: 546141-08-6 Cat. No.: U409162 Molecular Weight: 338.4 EC Number: 637-274-1 PubChem CID: 1383884

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

KDS-4103 | Carbamic acid, N-cyclohexyl-, 3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl ester

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

URB597 URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.
In vitro

URB597 binds in the hydrophobic pocket and catalytic core of FAAH that connects the active site residues to the membrane surface of FAAH. URB597 inhibits FAAH activity in human liver microsomes with IC50 of 3 nM. URB597 reduces the expression of the LPS-induced enzymes cyclo-oxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS; NOS2) in primary rat microglial cell, with a concomitant reduction in the release of the inflammatory mediators prostaglandin E2 (PGE2) and (NO) nitric oxide. URB597 evokes Ca₂₊ entry in HEK293-F Cells transiently expressing human or rat TRPA1 gene. URB597 also activates Ca₂₊ entry in rat DRG neurons natively expressed TRPA1 channels.

In vivo

URB597 inhibits [³H]anandamide hydrolysis in rat brain membranes with a parallel increase in brain anandamide, OEA, and PEA content by inhibition of FAAH. URB597 enhances the hypothermia effect induced by ethanolamide by inhibiting FAAH. When delivered intraperitonealy (0.3 mg/kg) URB597 reduces allodynia and hyperalgesia through cannabinoid CB1 and CB2 receptor-mediated analgesia in rats with inflammatory pain. URB597 reduces the reduction in body weight gain and sucrose intake induced by the chronic mild stress in rats through inhibition of brain FAAH activity. URB597 could reverse most depressive-like symptoms induced by adolescent THC exposure in femal rats.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyms

KDS-4103 | Carbamic acid, N-cyclohexyl-, 3'-(aminocarbonyl)[1, 1'-biphenyl]-3-yl ester

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

ACTIVATOR, INHIBITOR

Mechanism of action

Inhibitor of Fatty acid amide hydrolase;Inhibitor of Fatty acid amide hydrolase-2;Activator of TRPA1

Names and Identifiers

• Isomeric SMILES: C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N
• WGK Germany: 3
• PubChem CID: 1383884
• Molecular Weight: 338.4

Associated Targets(Human)

FAAH2 Tchem Fatty-acid amide hydrolase 2 (1 Activities)

Discover Target: FAAH2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

FAAH Tchem Fatty-acid amide hydrolase 1 (28 Activities)

Discover Target: FAAH

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

TRPA1 Tclin Transient receptor potential cation channel subfamily A member 1 (2 Activities)

Discover Target: TRPA1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)